USA flag logo/image

An Official Website of the United States Government

Safety of intraarticular N-acetylglucosamine

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
78058
Program Year/Program:
2006 / STTR
Agency Tracking Number:
AT003352
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ARTYX PHARMACEUTICALS, INC.
ARTYX PHARMACEUTICALS, INC. 9025 BALBOA AVE, SUITE 110 SAN DIEGO, CA 92123 0152
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2006
Title: Safety of intraarticular N-acetylglucosamine
Agency: HHS
Contract: 1R42AT003352-01
Award Amount: $845,835.00
 

Abstract:

DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most prevalent joint disease, causing joint pain and dysfunction. OA is also associated with substantial co-morbidity and reduces life expectancy. Pharmacologic therapy is limited to symptom modification and disease-modifying therapies are currently not available. Furthermore, even symptom-modifying therapies are limited in efficacy and can be associated with adverse reactions. This proposal is based on extensive prior work that identified N-acetylglucosamine (GlcNAc) as an agent with potential for both, symptom and disease modification in OA. GlcNAc has a spectrum of desirable activities in cell culture models and anti-inflammatory, analgesic and OA disease-modifying activity in animal models. The long-term goal of is to determine efficacy of repeated intraarticular injections of GlcNAc in the treatment of OA. Towards this goal we recently established safety of single intraarticular injections of up to 100mM GlcNAc in patients with knee OA. The next step and goal of the proposed STTR Phase I study is to establish safety of repetitive intraarticular injections of GlcNAc. Patients with knee OA will receive one injection of GlcNAc per week for three consecutive weeks. An escalating dosing scheme will be used including 1,10 and 100mM GlcNAc. Patients will be monitored for local and systemic adverse reactions.

Principal Investigator:

Martin K. Lotz
8587848960
MLOTZ@SCRIPPS.EDU

Business Contact:


8587366540
Small Business Information at Submission:

ARTYX PHARMACEUTICALS, INC.
ARTYX PHARMACEUTICALS, INC. 9025 BALBOA AVE, SUITE 110 SAN DIEGO, CA 92123

EIN/Tax ID: 710952352
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
SCRIPPS RESEARCH INSTITUTE
SCRIPPS RESEARCH INSTITUTE
10550 NORTH TORREY PINES ROAD
LA JOLLA, CA 92037
RI Type: Domestic nonprofit research organization